{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:50:20Z","timestamp":1790092220624,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Transthyretin (ATTR) amyloidosis is a progressive protein misfolding disease with frequent cardiac involvement. This review aims to determine the value of PET in diagnosis, assessment of disease progression or treatment response and its relation to clinical outcome in follow-up of ATTR amyloid cardiomyopathy (ATTR-CM) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Medline, Cochrane Library, Embase and Web of Science databases were searched, from the earliest date available until December 2022, for studies investigating the use of PET in ATTR-CM patients. Studies containing original data were included, except for case reports. Risk of bias was assessed by QUADAS-2.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-one studies were included in this systematic review, investigating five different tracers: carbon-11 Pittsburgh compound B ([<jats:sup>11<\/jats:sup>C]PIB), fluorine-18 Florbetaben ([<jats:sup>18<\/jats:sup>F]FBB), fluorine-18 Florbetapir ([<jats:sup>18<\/jats:sup>F]FBP), fluorine-18 Flutemetamol ([<jats:sup>18<\/jats:sup>F]FMM) and fluorine-18 Sodium Fluoride (Na[<jats:sup>18<\/jats:sup>F]F). In total 211 ATTR amyloidosis patients were included. A majority of studies concluded that [<jats:sup>11<\/jats:sup>C]PIB, [<jats:sup>18<\/jats:sup>F]FBP and Na[<jats:sup>18<\/jats:sup>F]F can distinguish ATTR amyloidosis patients from controls, and that [<jats:sup>11<\/jats:sup>C]PIB and Na[<jats:sup>18<\/jats:sup>F]F, but not [<jats:sup>18<\/jats:sup>F]FBP, can distinguish ATTR-CM patients from patients with cardiac light chain amyloidosis. Evidence on the performance of [<jats:sup>18<\/jats:sup>F]FBB and [<jats:sup>18<\/jats:sup>F]FMM was contradictory. No studies on the use of PET in follow-up were found.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>[<jats:sup>11<\/jats:sup>C]PIB, Na[<jats:sup>18<\/jats:sup>F]F and [<jats:sup>18<\/jats:sup>F]FBP can be used to diagnose cardiac amyloidosis, although [<jats:sup>18<\/jats:sup>F]FBP may not be suitable for the distinction of different types of amyloid cardiomyopathy. No studies on PET in the follow-up of ATTR amyloidosis patients were found. Future research should focus on the use of these PET tracers in the follow-up of ATTR amyloidosis patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06381-3","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T11:24:27Z","timestamp":1691666667000},"page":"93-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8572-9428","authenticated-orcid":false,"given":"H. S. A.","family":"Tingen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8414-958X","authenticated-orcid":false,"given":"A.","family":"Tubben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7666-1280","authenticated-orcid":false,"given":"J. H.","family":"van \u2019t Oever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3319-5484","authenticated-orcid":false,"given":"E. M.","family":"Pastoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9070-8080","authenticated-orcid":false,"given":"P. P. A.","family":"van Zon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3974-6830","authenticated-orcid":false,"given":"H. L. A.","family":"Nienhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-4413","authenticated-orcid":false,"given":"P.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-1164","authenticated-orcid":false,"given":"R. H J. A.","family":"Slart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"10038","key":"6381_CR1","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(15)01274-X.","journal-title":"Lancet"},{"issue":"2","key":"6381_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.rdc.2013.02.012","volume":"39","author":"BPC Hazenberg","year":"2013","unstructured":"Hazenberg BPC. Amyloidosis: A Clinical Overview. Rheum Dis Clin North Am. 2013;39(2):323\u201345. https:\/\/doi.org\/10.1016\/j.rdc.2013.02.012.","journal-title":"Rheum Dis Clin North Am."},{"issue":"4","key":"6381_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000506696","volume":"143","author":"MM Picken","year":"2020","unstructured":"Picken MM. The Pathology of Amyloidosis in Classification: A Review. Acta Haematol. 2020;143(4):322\u201334. https:\/\/doi.org\/10.1159\/000506696.","journal-title":"Acta Haematol."},{"issue":"16","key":"6381_CR4","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072.","journal-title":"Eur Heart J."},{"issue":"Suppl 2","key":"6381_CR5","doi-asserted-by":"publisher","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","volume":"18","author":"A Martinez-Naharro","year":"2018","unstructured":"Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018;18(Suppl 2):s30\u20135.","journal-title":"Clin Med (Lond)"},{"issue":"6","key":"6381_CR6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European J of Heart Fail. 2021;23(6):895\u2013905. https:\/\/doi.org\/10.1002\/ejhf.2198.","journal-title":"European J of Heart Fail."},{"issue":"4","key":"6381_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","volume":"3","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR Amyloidosis: Current and Emerging Management Strategies. JACC: CardioOncol. 2021;3(4):488\u2013505. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.006.","journal-title":"JACC: CardioOncol."},{"issue":"6","key":"6381_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jjcc.2020.07.003","volume":"76","author":"SH Kim","year":"2020","unstructured":"Kim SH, Kim YS, Kim S-J. Diagnostic performance of PET for detection of cardiac amyloidosis: A systematic review and meta-analysis. J Cardiol. 2020;76(6):618\u201325. https:\/\/doi.org\/10.1016\/j.jjcc.2020.07.003.","journal-title":"J Cardiol."},{"issue":"1","key":"6381_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10654-019-00576-5","volume":"35","author":"T Muka","year":"2020","unstructured":"Muka T, et al. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. Eur J Epidemiol. 2020;35(1):49\u201360. https:\/\/doi.org\/10.1007\/s10654-019-00576-5.","journal-title":"Eur J Epidemiol."},{"issue":"4","key":"6381_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jama.2017.19163","volume":"319","author":"MDF McInnes","year":"2018","unstructured":"McInnes MDF, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388. https:\/\/doi.org\/10.1001\/jama.2017.19163.","journal-title":"JAMA"},{"issue":"11","key":"6381_CR11","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.7326\/M21-2234","volume":"174","author":"B Yang","year":"2021","unstructured":"Yang B, et al. QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies. Ann Intern Med. 2021;174(11):1592\u20139. https:\/\/doi.org\/10.7326\/M21-2234.","journal-title":"Ann Intern Med"},{"issue":"2","key":"6381_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","volume":"54","author":"G Antoni","year":"2013","unstructured":"Antoni G, et al. In Vivo Visualization of Amyloid Deposits in the Heart with 11 C-PIB and PET. J Nucl Med. 2013;54(2):213\u201320. https:\/\/doi.org\/10.2967\/jnumed.111.102053.","journal-title":"J Nucl Med."},{"key":"6381_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.830572","volume":"9","author":"X Bi","year":"2022","unstructured":"Bi X, et al. Diagnostic Value of 11C-PIB PET\/MR in Cardiac Amyloidosis. Front. Cardiovasc. Med. 2022;9:830572. https:\/\/doi.org\/10.3389\/fcvm.2022.830572.","journal-title":"Front. Cardiovasc. Med."},{"issue":"6","key":"6381_CR14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","volume":"13","author":"S Rosengren","year":"2020","unstructured":"Rosengren S, et al. Diagnostic Accuracy of [11C]PIB Positron Emission Tomography for Detection of Cardiac Amyloidosis. JACC: Cardiovascul Imag. 2020;13(6):1337\u201347. https:\/\/doi.org\/10.1016\/j.jcmg.2020.02.023.","journal-title":"JACC: Cardiovascul Imag."},{"issue":"1","key":"6381_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12350-016-0638-5","volume":"25","author":"B Pilebro","year":"2018","unstructured":"Pilebro B, et al. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol. 2018;25(1):240\u20138. https:\/\/doi.org\/10.1007\/s12350-016-0638-5.","journal-title":"J Nucl Cardiol."},{"issue":"4","key":"6381_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/13506129.2020.1798223","volume":"27","author":"K Takasone","year":"2020","unstructured":"Takasone K, et al. Non-invasive detection and differentiation of cardiac amyloidosis using 99m Tc-pyrophosphate scintigraphy and 11 C-Pittsburgh compound B PET imaging. Amyloid. 2020;27(4):266\u201374. https:\/\/doi.org\/10.1080\/13506129.2020.1798223.","journal-title":"Amyloid"},{"issue":"3","key":"6381_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s00259-017-3814-1","volume":"45","author":"N Ezawa","year":"2018","unstructured":"Ezawa N, Katoh N, Oguchi K, Yoshinaga T, Yazaki M, Sekijima Y. Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging. Eur J Nucl Med Mol Imag. 2018;45(3):452\u201361. https:\/\/doi.org\/10.1007\/s00259-017-3814-1.","journal-title":"Eur J Nucl Med Mol Imag."},{"issue":"1","key":"6381_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","volume":"14","author":"D Genovesi","year":"2021","unstructured":"Genovesi D, et al. [18F]-Florbetaben PET\/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions. JACC: Cardiovas Imag. 2021;14(1):246\u201355. https:\/\/doi.org\/10.1016\/j.jcmg.2020.05.031.","journal-title":"JACC: Cardiovas Imag."},{"issue":"7","key":"6381_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","volume":"46","author":"M Kircher","year":"2019","unstructured":"Kircher M, et al. Detection of cardiac amyloidosis with 18F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imag. 2019;46(7):1407\u201316. https:\/\/doi.org\/10.1007\/s00259-019-04290-y.","journal-title":"Eur J Nucl Med Mol Imag."},{"issue":"11","key":"6381_CR20","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","volume":"57","author":"WP Law","year":"2016","unstructured":"Law WP, Wang WYS, Moore PT, Mollee PN, Ng ACT. Cardiac Amyloid Imaging with 18 F-Florbetaben PET: A Pilot Study. J Nucl Med. 2016;57(11):1733\u20139. https:\/\/doi.org\/10.2967\/jnumed.115.169870.","journal-title":"J Nucl Med."},{"issue":"4","key":"6381_CR21","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s12350-021-02608-8","volume":"29","author":"MF Santarelli","year":"2022","unstructured":"Santarelli MF, et al. Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images. J. Nucl. Cardiol. 2022;29(4):1919\u201332. https:\/\/doi.org\/10.1007\/s12350-021-02608-8.","journal-title":"J. Nucl. Cardiol."},{"issue":"9","key":"6381_CR22","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652\u201362. https:\/\/doi.org\/10.1007\/s00259-014-2787-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6381_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fcvm.2015.00023","volume":"2","author":"DR Osborne","year":"2015","unstructured":"Osborne DR, Acuff SN, Stuckey A, Wall JS. A Routine PET\/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using 18F-Florbetapir. Front. Cardiovasc. Med. 2015;2:23.","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"6381_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/13506129.2018.1467313","volume":"25","author":"J Mestre-Torres","year":"2018","unstructured":"Mestre-Torres J, et al. Utility of the 18 F-Florbetapir positron emission tomography in systemic amyloidosis. Amyloid. 2018;25(2):109\u201314. https:\/\/doi.org\/10.1080\/13506129.2018.1467313.","journal-title":"Amyloid"},{"issue":"8","key":"6381_CR25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","volume":"33","author":"S Dietemann","year":"2019","unstructured":"Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-flutemetamol positron emission tomography. Ann Nucl Med. 2019;33(8):624\u20138. https:\/\/doi.org\/10.1007\/s12149-019-01372-7.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"6381_CR26","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12350-020-02363-2","volume":"29","author":"M Papathanasiou","year":"2022","unstructured":"Papathanasiou M, et al. 18F-flutemetamol positron emission tomography in cardiac amyloidosis. J. Nucl. Cardiol. 2022;29(2):779\u201389. https:\/\/doi.org\/10.1007\/s12350-020-02363-2.","journal-title":"J. Nucl. Cardiol."},{"issue":"1","key":"6381_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12350-019-01675-2","volume":"28","author":"P Martineau","year":"2021","unstructured":"Martineau P, Finnerty V, Giraldeau G, Authier S, Harel F, Pelletier-Galarneau M. Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis. J. Nucl. Cardiol. 2021;28(1):209\u201318. https:\/\/doi.org\/10.1007\/s12350-019-01675-2.","journal-title":"J. Nucl. Cardiol."},{"issue":"2","key":"6381_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12350-020-02356-1","volume":"29","author":"JPM Andrews","year":"2022","unstructured":"Andrews JPM, et al. 18F-fluoride PET\/MR in cardiac amyloid: A comparison study with aortic stenosis and age- and sex-matched controls. J. Nucl. Cardiol. 2022;29(2):741\u20139. https:\/\/doi.org\/10.1007\/s12350-020-02356-1.","journal-title":"J. Nucl. Cardiol."},{"issue":"4","key":"6381_CR29","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s12350-019-01885-8","volume":"28","author":"M Abulizi","year":"2021","unstructured":"Abulizi M, et al. 18F-sodium fluoride PET\/MRI myocardial imaging in patients with suspected cardiac amyloidosis. J. Nucl. Cardiol. 2021;28(4):1586\u201395. https:\/\/doi.org\/10.1007\/s12350-019-01885-8.","journal-title":"J. Nucl. Cardiol."},{"issue":"24","key":"6381_CR30","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2016.09.953","volume":"68","author":"MG Trivieri","year":"2016","unstructured":"Trivieri MG, et al. 18 F-Sodium Fluoride PET\/MR for the Assessment of Cardiac Amyloidosis. J Ame College Cardiol. 2016;68(24):2712\u20134. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.953.","journal-title":"J Ame College Cardiol."},{"issue":"5","key":"6381_CR31","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s12350-017-0799-x","volume":"25","author":"R Morgenstern","year":"2018","unstructured":"Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. 18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J. Nucl. Cardiol. 2018;25(5):1559\u201367. https:\/\/doi.org\/10.1007\/s12350-017-0799-x.","journal-title":"J. Nucl. Cardiol."},{"issue":"3","key":"6381_CR32","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s12350-020-02425-5","volume":"29","author":"LX Zhang","year":"2022","unstructured":"Zhang LX, et al. Comparison of 18F-sodium fluoride positron emission tomography imaging and 99mTc-pyrophosphate in cardiac amyloidosis. J. Nucl. Cardiol. 2022;29(3):1132\u201340. https:\/\/doi.org\/10.1007\/s12350-020-02425-5.","journal-title":"J. Nucl. Cardiol."},{"issue":"3","key":"6381_CR33","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s12350-018-1349-x","volume":"27","author":"T Kero","year":"2020","unstructured":"Kero T, et al. Quantification of 11C-PIB kinetics in cardiac amyloidosis. J Nucl Cardiol. 2020;27(3):774\u201384. https:\/\/doi.org\/10.1007\/s12350-018-1349-x.","journal-title":"J Nucl Cardiol"},{"issue":"24","key":"6381_CR34","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404\u201312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612.","journal-title":"Circulation"},{"issue":"2","key":"6381_CR35","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s12350-020-02274-2","volume":"29","author":"D Bellevre","year":"2022","unstructured":"Bellevre D. Quantitation of myocardial 99mTc-HMDP uptake with new SPECT\/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: Ready for clinical use? J Nucll Cardiol. 2022;29(2):506\u201314.","journal-title":"J Nucll Cardiol"},{"issue":"2","key":"6381_CR36","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12350-020-02274-2","volume":"29","author":"L Kessler","year":"2022","unstructured":"Kessler L, et al. Quantitative 99mTc-DPD-SPECT\/CT assessment of cardiac amyloidosis. J Nucl Cardiol. 2022;29(2):506\u201314.","journal-title":"J Nucl Cardiol."},{"issue":"2","key":"6381_CR37","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12350-020-02340-9","volume":"29","author":"T Kudo","year":"2022","unstructured":"Kudo T, Imakhanova A. Quantification of amyloid deposition using bone scan agents. J Nucl Cardiol. 2022;29(2):515\u20138. https:\/\/doi.org\/10.1007\/s12350-020-02340-9.","journal-title":"J Nucl Cardiol."},{"issue":"6","key":"6381_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11886-020-01284-3","volume":"22","author":"C Gallegos","year":"2020","unstructured":"Gallegos C, Miller EJ. Advances in PET-Based Cardiac Amyloid Radiotracers. Curr Cardiol Rep. 2020;22(6):40. https:\/\/doi.org\/10.1007\/s11886-020-01284-3.","journal-title":"Curr Cardiol Rep."},{"issue":"7","key":"6381_CR39","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1161\/ATVBAHA.120.313785","volume":"40","author":"E Tzolos","year":"2020","unstructured":"Tzolos E, Dweck MR. 18 F-Sodium Fluoride ( 18 F-NaF) for Imaging Microcalcification Activity in the Cardiovascular System. ATVB. 2020;40(7):1620\u20136. https:\/\/doi.org\/10.1161\/ATVBAHA.120.313785.","journal-title":"ATVB"},{"issue":"5","key":"6381_CR40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","volume":"25","author":"MA Stats","year":"2016","unstructured":"Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovas Pathol. 2016;25(5):413\u20137. https:\/\/doi.org\/10.1016\/j.carpath.2016.07.001.","journal-title":"Cardiovas Pathol."},{"key":"6381_CR41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijcard.2022.01.036","volume":"352","author":"U Thelander","year":"2022","unstructured":"Thelander U, et al. Cardiac microcalcifications in transthyretin (ATTR) amyloidosis. Int J Cardio. 2022;352:84\u201391. https:\/\/doi.org\/10.1016\/j.ijcard.2022.01.036.","journal-title":"Int J Cardio."}],"updated-by":[{"DOI":"10.1007\/s00259-023-06408-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000}}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06381-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06381-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06381-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T08:07:33Z","timestamp":1701158853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06381-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6381"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06381-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00259-023-06408-9","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00259-023-06408-9","URL":"https:\/\/doi.org\/10.1007\/s00259-023-06408-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}